Although the therapeutic potential of CGRP has been limited because of its peptide nature and short half-life, cardiovascular research has recently put forward injectable and long-lasting CGRP analogues which exert antihypertensive effects, attenuate cardiac failure and improve metabolic parameters in mice [65,66]. The gene discussed is CALCA; the disease is heart failure.